Abstract
In open trials, 20 of 21 patients with major depression who developed insomnia during treatment with monoamine oxidase inhibitors (MAOIs) reported sustained hypnotic effects from trazodone 50 to 75 mg. Similarly, 26 of 27 mood disorder patients with insomnia unrelated to MAOIs reported improved sleep with low-dose trazodone. No negative interactions with MAOIs and other psychotropics were observed, side effects were minimal, and no tolerance to the hypnotic effects of trazodone occurred. Low-dose trazodone may be a safe and effective agent for treating MAOI-induced and other insomnias.
MeSH terms
-
Administration, Oral
-
Adult
-
Bipolar Disorder / drug therapy
-
Bipolar Disorder / psychology
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / psychology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Monoamine Oxidase Inhibitors / adverse effects*
-
Monoamine Oxidase Inhibitors / therapeutic use
-
Pilot Projects
-
Psychiatric Status Rating Scales
-
Psychotic Disorders / drug therapy
-
Psychotic Disorders / psychology
-
Psychotropic Drugs / adverse effects*
-
Psychotropic Drugs / therapeutic use
-
Sleep Initiation and Maintenance Disorders / chemically induced
-
Sleep Initiation and Maintenance Disorders / drug therapy*
-
Trazodone / administration & dosage*
-
Trazodone / therapeutic use
Substances
-
Monoamine Oxidase Inhibitors
-
Psychotropic Drugs
-
Trazodone